User:Mr. Ibrahem/Ibalizumab

Ibalizumab, sold under the brand name Trogarzo, is a medication used to treat HIV/AIDS. It is used, together with other medications, when standard treatments are not effective. It is given by injection into a vein.

Common side effects include rash, diarrhea, dizziness, headache, nausea, and tiredness. Other side effects may include immune reconstitution syndrome. Safety in pregnancy is unclear. It is a monoclonal antibody that binds to CD4 and prevents HIV from entering cells.

Ibalizumab was approved for medical use in the United States in 2018 and Europe in 2019. In the United States the initial dose costs about 13,400 USD, with further treatment about 11,000 USD per month as of 2021. It is not commercially available in the United Kingdom and Europe as of 2021.